NAD+ declines with age. Precursor supplementation raises it. Whether that translates to meaningful human longevity benefits is still being established.
By Dr. Teja V. Surapaneni, MD, MS • Board-Certified Internal Medicine • May 2026
NAD+ is a molecule involved in hundreds of metabolic reactions and several aging-related pathways. It declines with age. NMN and NR are precursors that raise NAD+ levels. Whether raising NAD+ meaningfully impacts human aging is still being established.
Nicotinamide adenine dinucleotide (NAD+) functions in two roles in human physiology:
Metabolic cofactor: NAD+ is required for glycolysis, the citric acid cycle, and oxidative phosphorylation. Without it, cells cannot efficiently convert food into ATP. Every macronutrient metabolism pathway runs through NAD+.
Signaling molecule: NAD+ is consumed (not merely recycled) by several aging-relevant enzyme families: sirtuins (SIRT1–7, which regulate DNA repair, mitochondrial biogenesis, inflammation, and gene expression) and PARPs (poly-ADP ribose polymerases, which repair DNA strand breaks). Both pathways consume NAD+ as a substrate. As DNA damage and metabolic stress increase with aging, these NAD+-consuming pathways become more active, accelerating the decline in available NAD+.
NAD+ levels in tissues decline approximately 50% between age 20 and 60 in humans. This decline is associated with — though not proven to cause — several hallmarks of aging: mitochondrial dysfunction, reduced DNA repair capacity, increased inflammation, and metabolic decline.
Direct NAD+ supplementation is not practical — the molecule does not efficiently enter cells from oral administration. Instead, the approach is to supplement with precursors that cells can convert to NAD+:
NR (Nicotinamide Riboside): Converted to NMN by NR kinase enzymes, then to NAD+ by NMNAT enzymes. NR has been studied in humans since approximately 2016. Multiple small trials show that oral NR raises blood NAD+ levels dose-dependently. Whether blood NAD+ levels reflect tissue NAD+ levels (particularly muscle and brain) is debated.
NMN (Nicotinamide Mononucleotide): One step closer to NAD+ than NR. Cells can convert NMN to NAD+ directly via NMNAT. A 2021 human trial by Yoshino et al. found that 250 mg/day NMN for 10 weeks in postmenopausal women with prediabetes improved muscle insulin sensitivity (as measured by the glucose infusion rate during hyperinsulinemic euglycemic clamp). This is the strongest human evidence to date for a clinically meaningful NMN effect.
A significant challenge in the NAD+ precursor field is CD38 — an enzyme that becomes more active with aging and degrades NAD+ (and its precursors). Studies in aged mice show that blocking CD38 raises NAD+ levels and improves metabolic function, even without precursor supplementation. This suggests that the primary driver of age-related NAD+ decline may not be insufficient synthesis from precursors, but excessive CD38-mediated degradation.
If the CD38 problem is primary, then supplementing with precursors is like trying to fill a bathtub with the drain open. Apigenin (a flavonoid found in chamomile and parsley) has been identified as a weak natural CD38 inhibitor and has been co-formulated with NMN in some products. The clinical evidence for apigenin as an NAD+ booster in humans is essentially nonexistent at this stage.
Yoshino J et al. (Cell Metabolism, 2021): 25 postmenopausal women with prediabetes, 250 mg/day NMN vs placebo for 10 weeks. Primary endpoint: muscle insulin sensitivity (hyperinsulinemic euglycemic clamp). Result: NMN significantly improved muscle insulin sensitivity vs placebo (p<0.05), without changes in body weight, liver fat, or systemic inflammation markers.
What this means: NMN has a plausible, measurable effect on one important metabolic endpoint in a specific population (postmenopausal women with prediabetes). What this does not mean: that NMN extends human lifespan, reverses aging broadly, or works equivalently in all populations. n=25 is a small trial; the effect needs replication in larger and more diverse populations.
David Sinclair, PhD (Harvard) is the most prominent proponent of NAD+ precursors for longevity and has significant financial interests in NMN-related companies. His advocacy has been instrumental in popularizing the space. This creates a potential conflict of interest that should be acknowledged when evaluating his public statements about NMN evidence. His lab’s mouse data is scientifically published and peer-reviewed; the translation to humans is less established than his public commentary sometimes implies.
This is not an ad hominem critique — Sinclair’s research contributions are real. It is a disclosure note that consumer decisions should incorporate.
NMN and NR are probably safe at commercially available doses. They reliably raise blood NAD+ levels. They have one decent human RCT (Yoshino 2021) showing a metabolic benefit in a specific population. They do not have evidence for lifespan extension, broad anti-aging effects, or cognitive improvement in humans. Multiple larger trials are underway as of 2026.
For patients who want to take NMN or NR: the risk/benefit ratio is probably favorable given the safety profile and mechanistic plausibility, with the explicit understanding that the human evidence is preliminary. 300–500 mg NMN or 250–500 mg NR daily are the doses used in trials. Evening dosing is sometimes recommended based on circadian NAD+ fluctuation data.
There is no definitive human trial comparing the two head-to-head. NMN is one step closer to NAD+ and may be more efficient. NR has a slightly longer human evidence track record. Both raise blood NAD+ levels. The practical difference at commercially available doses is likely small.
Yes. Blood and tissue NAD+ levels decline approximately 50% between age 20 and 60 in humans. This is well-established in the literature. Whether supplementing to restore levels improves meaningful aging outcomes in humans is still being studied.
The Yoshino et al. 2021 trial (Cell Metabolism) showed that 250 mg/day NMN improved muscle insulin sensitivity in postmenopausal women with prediabetes. This is the strongest human evidence for a clinically meaningful effect to date. Larger trials are ongoing.
Available evidence suggests NMN and NR are safe at commercially available doses (250-500 mg/day). No serious adverse events have been reported in clinical trials. Long-term safety data beyond 12 months in humans is limited. Avoid very high doses until more data is available.
This article is for informational purposes only and does not constitute medical advice. Always consult with a licensed physician before starting any medication.
No credit card required. Live MD consult included.